Skip to main content
Smart Investors Daily
SE

NASDAQ · SEPN

Septerna, Inc. Common Stock

Healthcare · Biotechnology

$41.67

Down-$0.93 (-2.18%)

Updated Nov 17, 2026, 5:34 AM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.17B
P/E ratio
-19.76
Dividend yield
0.00%
52-week range
$18.64 – $53.34
Volume
385.34K
Avg. volume
331.52K

Price performance · SEPN

SEPN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

SEPN closed at $41.67 after 21 trading sessions, up 14.54% for the selected period.

Last close
$41.67
Period change
+14.54%
Period low
$36.38
Period high
$52.34
Daily close
View OHLC price history
SEPN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$42.86$43.00$40.825$41.67385.34K
Nov 13, 2026$41.27$42.8825$40.6001$42.60337.79K
Nov 12, 2026$47.89$48.285$41.65$41.86608.54K
Nov 11, 2026$51.90$53.34$45.26$48.561.13M
Nov 10, 2026$49.35$52.535$46.8401$52.34537.69K
Nov 9, 2026$49.86$50.82$48.07$50.74713.68K
Nov 6, 2026$48.20$51.05$47.8448$48.85384.55K
Nov 5, 2026$47.90$48.10$45.95$47.35533.99K
Nov 4, 2026$45.60$48.225$44.79$47.88604.92K
Nov 3, 2026$43.53$44.58$42.22$43.70307.51K
Nov 2, 2026$44.06$44.95$41.07$43.20475.33K
Oct 30, 2026$45.00$45.4315$43.68$44.00223.45K
Oct 29, 2026$44.43$45.60$43.74$45.23200.69K
Oct 28, 2026$43.51$45.08$41.92$44.25380.14K
Oct 27, 2026$41.43$44.22$40.97$44.14261.83K
Oct 26, 2026$40.42$41.95$38.393$41.38279.43K
Oct 23, 2026$40.63$41.21$39.65$40.41200.32K
Oct 22, 2026$40.72$41.77$39.70$40.88251.11K
Oct 21, 2026$39.57$41.40$38.75$40.76286.4K
Oct 20, 2026$36.46$39.55$36.25$39.35418.31K
Oct 19, 2026$36.48$37.82$36.035$36.38410.19K

Latest SEPN news

The latest Smart Investors Daily articles mentioning SEPN.

SEPN research

Overview

Company profile and research snapshot.

Company profile

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$28.00
Implied upside
—
Analysts
—
SEPN recent ratings
DateFirmRatingTarget
Nov 10, 2026StifelBuy—
Nov 6, 2026GuggenheimBuy—
Nov 4, 2026Wells FargoOverweight—
Aug 19, 2026JP MorganOverweight—
Aug 13, 2026Jones TradingBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 10, 2026

What Septerna Shares Profit To Loss Swing Means For Shareholders

Septerna reported third quarter 2026 sales of US$18.88 million and a net loss of US$26.59 million, compared with net income a year earlier, alongside higher nine month sales of US$72.15 million and a wider cumulative loss. The swing from earnings of US$0.18 per basic share in the prior third quarter to a basic loss of US$0.57 this quarter highlights how current operating costs and investment needs are weighing on Septerna's path to profitability. We will now examine how Septerna's investment...

Yahoo · Nov 9, 2026

Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results

Phase 1 Clinical Trial for PTH1R Agonist SEP-479 Ongoing; SAD / MAD Data Expected in Q1 2027 Plans to Initiate Phase 1 Clinical Trial of Newly Selected Oral TSHR NAM Development Candidate SEP-204 in Q1 2027 Cash Position of $565.2 Million Expected to Support Operating Plans at Least into mid-2029 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discov

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.